ClinicalTrials.gg
Sign In

Pleural Effusion, Malignant clinical trials

The registry lists 169 studies for Pleural Effusion, Malignant across more than 10 countries. 39 are recruiting or about to start. 124 of them are mainly about Pleural Effusion, Malignant (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Pleural Effusion, Malignant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
68
Status unknown
36
Recruiting
25
Terminated
18
Not yet recruiting
13
Withdrawn
5

Phase

Phase 2
42
Phase 1
34
Phase 3
10
Phase 4
9
Early Phase 1
5

Where

United States
52
China
30
United Kingdom
16
Denmark
7
Egypt
7
Canada
7

Who runs them

National Cancer Institute (NCI) (8) · Naestved Hospital (6) · Assiut University (6) · M.D. Anderson Cancer Center (5) · The University of Hong Kong (4) · Post Graduate Institute of Medical Education and Research, Chandigarh (3) · H. Lee Moffitt Cancer Center and Research Institute (3) · Jemincare (2)

What is being tested here

Drugs under test in Pleural Effusion, Malignant studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
JMKX000197303
Interleukin-2202
Aflutinib101
Tocilizumab101
MT027101
Bevacizumab016
Carboplatin005
Cisplatin004
Paclitaxel003
Docetaxel003

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 1 open · Angiogenesis inhibitors 7 · Antimitotic agents 5 · Antimetabolites 5 · Immune checkpoint inhibitors 3

Coming up

1phase 3 study under way
7studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 7

Who these studies take

Of the 25 Pleural Effusion, Malignant studies recruiting now, 15 (60%) set no upper age limit and 5 (20%) stop at 75 or younger. 3 (12%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (4%) take healthy volunteers.

Recruiting studies that take each age, of 25
AgeWomenMen
103 (12%)3 (12%)
1825 (100%)25 (100%)
3025 (100%)25 (100%)
4025 (100%)25 (100%)
5025 (100%)25 (100%)
6525 (100%)25 (100%)
7525 (100%)25 (100%)
8518 (72%)18 (72%)

Across all 169 studies, recruiting or not: 11% stop at 75 or younger and 1% at 65; 8% take children; 2% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Pleural Effusion, Malignant studies take

Of 22 observational studies under Pleural Effusion, Malignant, half reached primary completion within 27 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Observational27 mo12–44 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Newly registered2

Studies

Recruiting first, then most recently updated. Showing 50 of 169. Browse all 169 → or search them.